CA2097732A1 - Composition comprising r-alpha-lipoic acid and vitamin e for treating diabetes mellitus - Google Patents

Composition comprising r-alpha-lipoic acid and vitamin e for treating diabetes mellitus

Info

Publication number
CA2097732A1
CA2097732A1 CA002097732A CA2097732A CA2097732A1 CA 2097732 A1 CA2097732 A1 CA 2097732A1 CA 002097732 A CA002097732 A CA 002097732A CA 2097732 A CA2097732 A CA 2097732A CA 2097732 A1 CA2097732 A1 CA 2097732A1
Authority
CA
Canada
Prior art keywords
alpha
lipoic acid
acid
vitamin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002097732A
Other languages
French (fr)
Other versions
CA2097732C (en
Inventor
Carl-Heinrich Weischer
Heinz Ulrich
Klaus Wessel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2097732A1 publication Critical patent/CA2097732A1/en
Application granted granted Critical
Publication of CA2097732C publication Critical patent/CA2097732C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The use of alpha-lipoic acid, dihydrolipoic acid, metabolites of alpha-lipoic acid, inter alia 6,8-bisnortetralipoic acid, tetranorlipoic acid, optical isomers R- and S-form of alpha-lipoic acid in oxidized and reduced form in combination with vitamin A, B1, B2, B6, B12, C and E
and their pharmaceutically acceptable salts for the preparation of medicaments with analgesic, anti-inflammatory, antidiabetic, cytoprotective, anti-ulcer, antinecrotic, neuroprotective, detoxifying, anti-ischemic, liver function regulating, anti-allergic, immune-stimulating and antioncogenic effect, corresponding medicaments and their preparation.
CA002097732A 1992-06-05 1993-06-04 Composition comprising r-alpha-lipoic acid and vitamin e for treating diabetes mellitus Expired - Lifetime CA2097732C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4218572.6 1992-06-05
DE4218572A DE4218572A1 (en) 1992-06-05 1992-06-05 Synergistic combination of drugs containing as active ingredient alpha-lipoic acid, dihydrolipoic acid, their metabolites as well as the oxidized and reduced enantiomers of alpha-lipoic acid such as R-alpha-lipoic acid or S-alpha-lipoic acid and metabolites of alpha-lipoic acid with vitamins A, B1 -6, B12, C and E

Publications (2)

Publication Number Publication Date
CA2097732A1 true CA2097732A1 (en) 1993-12-06
CA2097732C CA2097732C (en) 2002-12-31

Family

ID=6460469

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002097732A Expired - Lifetime CA2097732C (en) 1992-06-05 1993-06-04 Composition comprising r-alpha-lipoic acid and vitamin e for treating diabetes mellitus

Country Status (4)

Country Link
EP (1) EP0572922A1 (en)
JP (2) JPH06135832A (en)
CA (1) CA2097732C (en)
DE (1) DE4218572A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476233B2 (en) 2003-08-29 2013-07-02 Therapeutic Research, Llc Methods for treatment for ulcerative colitis in mammals
US8809308B2 (en) 2012-11-09 2014-08-19 Scidose, Llc Enema composition for treatment of ulcerative colitis having long term stability
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320117A1 (en) * 1992-01-18 1994-12-22 Margarethe Rabien Combination products
DE4345199C2 (en) * 1993-05-22 1995-10-12 Asta Medica Ag Use of dihydrolipoic acid to suppress intolerance reactions in the border area of implants with living body tissue
DE4338508A1 (en) * 1993-11-11 1995-05-18 Asta Medica Ag Pharmaceutical preparations containing thioctic acid or dihydroliponic acid in the form of inclusion compounds with cyclodextrins or cyclodextrin derivatives and in the form of granules, chewable or effervescent tablets
DE4343592C2 (en) * 1993-12-21 1998-04-16 Asta Medica Ag Use of R - (+) - alpha-lipoic acid and its metabolites in the form of the free acid or as salts or esters or amides for the treatment of glucose metabolic disorders in the central nervous system
DE4343593C2 (en) 1993-12-21 1998-05-20 Asta Medica Ag Use of R - (+) - alpha-lipoic acid, R - (-) - dihydrolipoic acid or the metabolites as well as their salts, esters, amides for the treatment of compensated and decompensated insulin resistance
DE4433764A1 (en) * 1994-09-22 1996-03-28 Asta Medica Ag Dosage forms containing alpha-lipoic acid, solid salts of R-thioctic acid with improved release and bioavailability
DE4439480C1 (en) * 1994-11-08 1996-06-05 Asta Medica Ag Use of D, L-alpha-lipoic acid and / or its enantiomers, and / or their derivatives as an additive in red cell liquid preserves for homologous and autologous erythrocyte concentrates and as an additive in erythrocyte cryoconserves for homologous and autologous erythrocyte concentrates
US5709868A (en) * 1995-09-20 1998-01-20 Perricone; Nicholas V. Lipoic acid in topical compositions
WO1998023606A1 (en) * 1996-11-27 1998-06-04 Fuji Kagaku Kogyo Kabushiki Kaisha Cyclic dithio derivatives, remedies for diabetic kidney diseases, hypoglycemic agents, hypolipidemic agents, and lenitives for digestive disorders
EP0855396A1 (en) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
DE19705555A1 (en) * 1997-02-13 1998-08-20 Ulrich Dr Posanski Thioctic acid pharmaceutical preparations for oral use
DE19810336A1 (en) * 1998-03-11 1999-09-23 Asta Medica Ag Thioctic acid useful for pharmaceutical, cosmetic and nutritional purposes e.g. as an analgesic, antiinflammatory or antioxidant
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US6284786B1 (en) 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
US20040235950A1 (en) * 1999-05-20 2004-11-25 Voorhees John J. Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
DE19941217A1 (en) * 1999-08-30 2001-03-15 Asta Medica Ag Treatment of migraines by administration of alpha-lipoic acid or derivatives thereof
DE19954321A1 (en) * 1999-11-11 2001-07-26 Asta Medica Ag Facilitated administration of alpha lipoic acid or derivatives thereof
AU2000231423A1 (en) * 2000-03-03 2001-09-12 Shu-Wen Lee Specific therapeutic composition for treating aids
PT1294353E (en) * 2000-06-06 2006-07-31 Basf Ag USE OF LIPOIC ACID ENANTIOMER (R) IN COSMETIC AND DERMATOLOGICAL COMPOSITIONS
DE10027968A1 (en) * 2000-06-08 2001-12-13 Asta Medica Ag Adjuvant therapy of dementia using alpha-lipoic acid or derivative, is effective in combination with antidementia or neurotransmission improving agents in improving cognitive function in e.g. Alzheimer's disease patients
DE10111048A1 (en) * 2001-03-06 2002-09-12 Beiersdorf Ag Alpha-lipoic acid is used in cosmetics or dermatological compositions as an agent to regenerate stressed (especially aged) skin
MXPA03009737A (en) * 2001-04-30 2005-03-07 Trommsdorff Arzneimittel Pharmaceutically active uridine esters.
DE10125882B4 (en) * 2001-05-28 2007-03-29 Esparma Gmbh Medicaments containing ambroxol, its salts and / or prodrugs together with α-lipoic acid in the context of the treatment of diabetes mellitus
EP1273297A1 (en) * 2001-07-06 2003-01-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction)
DE20203244U1 (en) 2002-03-01 2002-05-23 Meins, Wolfgang, Prof. Dr., 22391 Hamburg Pharmaceutical composition for the prevention of Alzheimer's dementia
DE10223882A1 (en) 2002-05-29 2003-12-18 Degussa Flowable composition containing powdered lipoic acid (derivatives)
DE10229995A1 (en) * 2002-07-03 2004-01-15 Beiersdorf Ag Cosmetic or dermatological compositions containing alpha-lipoic acid are stabilized against breakdown by adjusting the pH to 7.1-8.5
DE10258239A1 (en) * 2002-12-13 2004-06-24 Degussa Ag Formulation used for treating non-chronic alcoholic intoxication, contains alpha-lipoic acid for scavenging free radicals and activating alcohol metabolizing enzymes
JP4849792B2 (en) * 2004-09-14 2012-01-11 オリザ油化株式会社 Cosmetic composition
DE102004050353A1 (en) * 2004-10-15 2006-04-20 Basf Ag Use of stable ammonium salts of lipoic acid for the treatment of diabetic and other disorders
WO2006042666A1 (en) * 2004-10-18 2006-04-27 Meda Pharma Gmbh & Co. Kg R-(+)-α-LIPONIC ACID FOR THE PREVENTION OF DIABETES
JP2006129841A (en) * 2004-11-09 2006-05-25 Nof Corp alpha-LIPOIC ACID-CONTAINING AQUEOUS COMPOSITION
DE102004060914A1 (en) * 2004-12-17 2006-07-06 Bioghurt Biogarde Gmbh & Co. Kg Use of lipoic acid-containing cyclodextrin complexes
JP4818637B2 (en) * 2005-05-02 2011-11-16 日本メナード化粧品株式会社 Low density lipoprotein (LDL) oxidation inhibitor
JP2007016000A (en) * 2005-07-11 2007-01-25 Taiyo Kagaku Co Ltd Thioctic acid-containing composition
WO2007032340A1 (en) * 2005-09-12 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. COMPOSITION CONTAINING α-LIPOIC ACID
JP4703388B2 (en) * 2005-12-06 2011-06-15 植田製油株式会社 Thioctic acid composition and method for producing the same
WO2009054458A1 (en) * 2007-10-25 2009-04-30 Nutri Co., Ltd. Composition for reducing the level of glucose, malondialdehyde-modified ldl, homocysteine and/or c-reactive protein in blood
US10632089B2 (en) 2015-04-18 2020-04-28 Jo Cosmetics Co., Ltd. Tyrosinase activity inhibitor and external preparation for skin
US20240041861A1 (en) * 2020-04-21 2024-02-08 Ned Biosystems, Inc. Compositions and methods for treatment and prophylaxis of viral infections
CN116637106A (en) * 2022-02-15 2023-08-25 四川大学 Health care product or medicine with antioxidation effect
CN115040521B (en) * 2022-05-10 2023-09-22 金陵科技学院 Application of B-vitamin and butyrate composition in preparation of medicines for killing gastric cancer cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127012A3 (en) * 1983-05-30 1987-05-27 Suntory Limited Antimutagenic agent and a method of reducing mutagenicity
PT95826B (en) * 1989-11-09 1997-11-28 Asta Medica Ag PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING AS ACTIVE INGREDIENT R-ALPHA-LIPONIC ACID OR S-ALPHA-LIPONIC ACID
IE67874B1 (en) * 1989-11-09 1996-05-01 Asta Medica Ag Medicaments containing as active substance sulphur-containing carboxylic acids and their use in combating retroviruses
DE9200543U1 (en) * 1992-01-18 1992-05-07 Rabien, Margarethe, 65239 Hochheim Ataxia medication in which a-lipoic acid + pantothenic acid or dexpanthenol are combined (also against MS, muscular atrophy, polyneuropathy, etc.)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476233B2 (en) 2003-08-29 2013-07-02 Therapeutic Research, Llc Methods for treatment for ulcerative colitis in mammals
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
US10064877B2 (en) 2003-08-29 2018-09-04 Therapeutic Research, Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
US8809308B2 (en) 2012-11-09 2014-08-19 Scidose, Llc Enema composition for treatment of ulcerative colitis having long term stability

Also Published As

Publication number Publication date
JP2004217669A (en) 2004-08-05
JPH06135832A (en) 1994-05-17
DE4218572A1 (en) 1993-12-09
CA2097732C (en) 2002-12-31
EP0572922A1 (en) 1993-12-08

Similar Documents

Publication Publication Date Title
CA2097732A1 (en) Composition comprising r-alpha-lipoic acid and vitamin e for treating diabetes mellitus
AU1769088A (en) A composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
EP0958816A3 (en) Medicament for the treatment of diabetes mellitus as well as its subsequent disorders
CA2039197A1 (en) Pharmaceutic Formulation for the Treatment of Alcoholism
GB1509979A (en) Pharmaceutical compositions containing aspirin or indomethacin
AU6194694A (en) Nor-bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
AU6933291A (en) Controlled absorption naproxen formulation for once-daily administration
AU7177794A (en) Absorption enhancers for drug administration
CA2119762A1 (en) Therapeutic inhibition of platelet aggregation by nucleophile-nitric oxide complexes and derivatives thereof
DE3680137D1 (en) PYRIDAZINE DERIVATIVES, THEIR PRODUCTION AND INSECTICIDES, ACARICIDES, NEMATICIDES, FUNGICIDAL COMPOSITIONS.
AU5195593A (en) Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
AU7472191A (en) Therapeutic composition containing a phenol compound and propolis useful against lipidic capside viruses, especially the herpes viruses
AU1180592A (en) 4-desoxy-4-epipodophyllotoxin derivative or pharmaceutically acceptable salt thereof
AU6073398A (en) Colchicine and thiocolchicine derivatives with antiflammatory and muscle relaxant activities
AU4278897A (en) 10,13,15-Trioxatricyclo(9.2.1.1.9.6)-Pentadecanone derivatives, method for the production thereof and medicaments containing these compounds
DE3577986D1 (en) SUBSTITUTED AZETIDINONE COMPOUNDS, THEIR PRODUCTION AND THEIR CONTAINING MEDICINAL PRODUCTS.
CA2103825A1 (en) 17-hydroxyiminomethyl-5.beta., 14.beta.-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same
EP0627436A4 (en) Carcinostatic compound and production thereof.
AU3859193A (en) New thiochroman compounds, processes for the preparation thereof, and pharmaceutical compositions containing them
DE3578597D1 (en) 4-PHENYLPHTHALAZINE DERIVATIVES, THE PRODUCTION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AU2808492A (en) Medicament composition for topical application
IE45418L (en) Thiazole derivative
IE780862L (en) Naphthyridines
ES2032476T3 (en) A PROCEDURE FOR PREPARING NEW 2-ANILINOTIAZOLINE DERIVATIVES.
ATE165239T1 (en) ORAL MEDICINAL PREPARATION CONTAINING DICLOFENAC SODIUM AND AN ORGANIC ACID

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130604

MKEC Expiry (correction)

Effective date: 20131009